Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on April 18, 2018. The report discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On April 18, 2018, the Board of Directors elected Seth Blackley, the Company's President and Co-Founder, as a Class I director. Stockholders party to the Stockholders Agreement dated June 4, 2015, indicated their support for this election.
Guidance, Outlook, and Management Commentary
- Compensation: Mr. Blackley will not receive any fees for his service on the Board. His compensation as an executive officer was previously disclosed in the Proxy Statement on Schedule 14A filed on April 27, 2017.
- Indemnification: Mr. Blackley will have the same director and officer indemnification arrangements described in the Company's Form S-3 Registration Statement filed on August 7, 2017.
- Related Party Transactions: As of the report date, neither Mr. Blackley nor his immediate family members are parties to any transactions requiring disclosure under Item 404(a) of Regulation S-K.
- Arrangements: There was no arrangement or understanding between Mr. Blackley and other persons regarding his selection as a director.
Key Facts for Investor Verification
- Confirmation of Seth Blackley's new role as a Class I director alongside his existing role as President and Co-Founder.
- Review of the Proxy Statement on Schedule 14A (filed April 27, 2017) for details on Mr. Blackley's executive compensation.
- Verification of the Company's Form S-3 Registration Statement (filed August 7, 2017) for director indemnification terms.